## Anna R Giuliano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5000716/publications.pdf

Version: 2024-02-01

234 papers

15,131 citations

28242 55 h-index 20343 116 g-index

237 all docs

237 docs citations

times ranked

237

9413 citing authors

#	Article	IF	Citations
1	Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial. Clinical Infectious Diseases, 2022, 74, 1247-1256.	2.9	8
2	Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men. Contemporary Clinical Trials, 2022, 115, 106592.	0.8	15
3	Hepatitis C Virus Screening: Factors Associated With Test Completion in a Large Academic Health Care System. Public Health Reports, 2022, 137, 1136-1145.	1.3	1
4	Oral human papillomavirus (HPV) and associated factors among healthy populations: The design of the PROGRESS (PRevalence of Oral hpv infection, a Global aSSessment) study. Contemporary Clinical Trials, 2022, 115, 106630.	0.8	3
5	Initiation of three complementary international studies investigating prevalence of oral HPV infection, burden of HPV-related head and neck disease, and efficacy of 9-valent HPV vaccination against oral HPV persistent infection. Contemporary Clinical Trials, 2022, 115, 106629.	0.8	2
6	Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial. The Lancet Child and Adolescent Health, 2022, 6, 38-48.	2.7	7
7	Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources. Expert Review of Vaccines, 2022, 21, 227-240.	2.0	6
8	Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Lancet Infectious Diseases, The, 2022, 22, 413-425.	4.6	50
9	Increasing HPV vaccination coverage to prevent oropharyngeal cancer: A cost-effectiveness analysis. Tumour Virus Research, 2022, 13, 200234.	1.5	4
10	Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study. The Lancet Regional Health Americas, 2022, 8, 100143.	1.5	25
11	COVID-19 vaccine behaviors and intentions among a national sample of United States adults ages 18–45. Preventive Medicine, 2022, 160, 107038.	1.6	12
12	Prevalence and persistence of HPV-16 molecular variants in the anal canal of men: The HIM study. Journal of Clinical Virology, 2022, 149, 105128.	1.6	2
13	Methylation of <scp>HPV16</scp> and <i>EPB41L3</i> in oral gargles and the detection of early and late oropharyngeal cancer. Cancer Medicine, 2022, 11, 3735-3742.	1.3	1
14	The Association between Smoking and Anal Human Papillomavirus in the HPV Infection in Men Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1546-1553.	1.1	5
15	Strategies and Lessons Learned During Cleaning of Data From Research Panel Participants: Cross-sectional Web-Based Health Behavior Survey Study. JMIR Formative Research, 2022, 6, e35797.	0.7	9
16	Hepatitis C virus (HCV) seroprevalence, RNA detection, and genotype distribution across Florida, 2015–2018. Preventive Medicine, 2022, 161, 107136.	1.6	1
17	Factors Associated With Persistence and Clearance of High-Risk Oral Human Papillomavirus (HPV) Among Participants in the HPV Infection in Men (HIM) Study. Clinical Infectious Diseases, 2021, 73, e3227-e3234.	2.9	13
18	Diversity of human papillomavirus in the anal canal of HIV-positive and HIV-negative men. Journal of Infection, 2021, 82, 112-116.	1.7	3

#	Article	IF	CITATIONS
19	Cutaneous viral infections associated with ultraviolet radiation exposure. International Journal of Cancer, 2021, 148, 448-458.	2.3	8
20	Sex Work and High-Risk Anal Human Papillomavirus Infection Among Transgender Women: The Condesa Study. Transgender Health, 2021, 6, 315-324.	1.2	2
21	Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?. Preventive Medicine, 2021, 144, 106321.	1.6	12
22	A world without cervical cancer is within our reach. Preventive Medicine, 2021, 144, 106462.	1.6	4
23	Using the Electronic Health Record to Characterize the Hepatitis C Virus Care Cascade. Public Health Reports, 2021, , 003335492110058.	1.3	3
24	T Cell Receptor Repertoires Acquired via Routine Pap Testing May Help Refine Cervical Cancer and Precancer Risk Estimates. Frontiers in Immunology, 2021, 12, 624230.	2.2	3
25	Seroprevalence of Chlamydia trachomatis, herpes simplex 2, Epstein-Barr virus, hepatitis C and associated factors among a cohort of men ages 18–70 years from three countries. PLoS ONE, 2021, 16, e0253005.	1.1	5
26	Association between Human Polyomaviruses and Keratinocyte Carcinomas: A Prospective Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1761-1764.	1.1	4
27	Sequential acquisition of human papillomavirus infection between genital and oral anatomic sites in males. International Journal of Cancer, 2021, 149, 1483-1494.	2.3	3
28	Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas. Cancer Research, 2021, 81, 4628-4638.	0.4	15
29	Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome. PLoS ONE, 2021, 16, e0254161.	1.1	4
30	The role of external genital lesions in HIV seroconversion among men participating in a multinational study. Sexually Transmitted Diseases, 2021, Publish Ahead of Print, 55-58.	0.8	0
31	Increases in HPV- $16/18$ antibody avidity and HPV-specific memory B-cell response in mid-adult aged men post-dose three of the quadrivalent HPV vaccine. Vaccine, 2021, 39, 5295-5301.	1.7	1
32	Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. JAMA Network Open, 2021, 4, e2124502.	2.8	58
33	Factors Associated with Screening Baby Boomers for Hepatitis C Virus Infection Among Primary Care Providers: a Retrospective Analysis. Journal of General Internal Medicine, 2021, 36, 3584-3586.	1.3	1
34	Methylation of HPV 16 and <i>EPB41L3</i> in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics. International Journal of Cancer, 2020, 146, 1018-1030.	2.3	18
35	Viruses in Skin Cancer (VIRUSCAN): Study Design and Baseline Characteristics of a Prospective Clinic-Based Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 39-48.	1.1	7
36	Oral human papillomavirus prevalence and type distribution by country (Brazil, Mexico and the United) Tj ETQqi	0 0 0 rgBT 2.3	/Overlock 10 T 11

#	Article	IF	Citations
37	Human Papillomavirus Infection and Related Diseases Among Men. , 2020, , 179-194.		О
38	There's just not enough time: a mixed methods pilot study of hepatitis C virus screening among baby boomers in primary care. BMC Family Practice, 2020, 21, 248.	2.9	3
39	Human Papillomavirus Vaccination Prevalence Among Adults Aged 19–45 Years: An Analysis of the 2017 National Health Interview Survey. American Journal of Preventive Medicine, 2020, 59, 837-849.	1.6	16
40	Differences in Factors Associated With High- and Low-Risk Oral Human Papillomavirus Genotypes in Men. Journal of Infectious Diseases, 2020, 223, 2099-2107.	1.9	0
41	Oral HPV prevalence assessment by Linear Array vs. SPF10 PCR-DEIA-LiPA25 system in the HPV Infection in Men (HIM) study. Papillomavirus Research (Amsterdam, Netherlands), 2020, 9, 100199.	4.5	7
42	Prevalence, incidence, and natural history of HPV infection in adult women ages 24 to 45 participating in a vaccine trial. Papillomavirus Research (Amsterdam, Netherlands), 2020, 10, 100202.	4.5	27
43	IPVS statement on "Temporary HPV vaccine shortage: Implications globally to achieve equityâ€; Papillomavirus Research (Amsterdam, Netherlands), 2020, 9, 100195.	4.5	19
44	Variants in immune-related genes and genital HPV 16 persistence in men. Papillomavirus Research (Amsterdam, Netherlands), 2019, 7, 11-14.	4.5	4
45	An environmental scan to examine stakeholder perspectives on human papillomavirus vaccination: A mixed methods study. Vaccine, 2019, 37, 187-194.	1.7	6
46	Untangling the dynamics of persistence and colonization in microbial communities. ISME Journal, 2019, 13, 2998-3010.	4.4	3
47	Electronic medical recordâ€verified hepatitis C virus screening in a large health system. Cancer Medicine, 2019, 8, 4555-4564.	1.3	10
48	HPV-specific antibodies at the oral cavity up to 30†months after the start of vaccination with the quadrivalent HPV vaccine among mid-adult aged men. Vaccine, 2019, 37, 2864-2869.	1.7	12
49	The association between body mass index and anal canal human papillomavirus prevalence and persistence: the HIM study. Human Vaccines and Immunotherapeutics, 2019, 15, 1911-1919.	1.4	7
50	Human Papillomavirus Genotype Detection in Oral Gargle Samples Among Men With Newly Diagnosed Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 460.	1.2	12
51	Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecologic Oncology, 2019, 154, 110-117.	0.6	62
52	Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men. Vaccine, 2019, 37, 2502-2510.	1.7	13
53	Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey. Cancer Epidemiology, 2019, 60, 112-120.	0.8	14
54	Oral gargle-tumor biopsy human papillomavirus (HPV) agreement and associated factors among oropharyngeal squamous cell carcinoma (OPSCC) cases. Oral Oncology, 2019, 92, 85-91.	0.8	13

#	Article	IF	CITATIONS
55	Human Papillomavirus and Genital Disease in Men: What We Have Learned from the <b><i>HIM Study</i></b> . Acta Cytologica, 2019, 63, 109-117.	0.7	22
56	Excess HPVâ€related head and neck cancer in the world trade center health program general responder cohort. International Journal of Cancer, 2019, 145, 1504-1509.	2.3	7
57	New directions in penile cancer. Lancet Oncology, The, 2019, 20, 16-17.	5.1	2
58	Genital Wart Recurrence Among Men Residing in Brazil, Mexico, and the United States. Journal of Infectious Diseases, 2019, 219, 703-710.	1.9	11
59	Cutaneous Viral Infections Across 2 Anatomic Sites Among a Cohort of Patients Undergoing Skin Cancer Screening. Journal of Infectious Diseases, 2019, 219, 711-722.	1.9	12
60	An Examination of HPV16 Natural Immunity in Men Who Have Sex with Men (MSM) in the HPV in Men (HIM) Study. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 496-502.	1.1	19
61	Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges. Vaccine, 2018, 36, 2705-2711.	1.7	16
62	Acquisition, Persistence, and Clearance of Human Papillomavirus Infection Among Male Virgins Residing in Brazil, Mexico, and the United States. Journal of Infectious Diseases, 2018, 217, 767-776.	1.9	17
63	Hepatitis C Virus Screening Trends: Serial Cross-Sectional Analysis of the National Health Interview Survey Population, 2013–2015. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 503-513.	1.1	39
64	Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leukemia and Lymphoma, 2018, 59, 911-917.	0.6	16
65	Florida physicians' reported use of AFIX-based strategies for human papillomavirus vaccination. Preventive Medicine, 2018, 116, 143-149.	1.6	7
66	Generation of a novel next-generation sequencing-based method for the isolation of new human papillomavirus types. Virology, 2018, 520, 1-10.	1.1	25
67	Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33,) Tj ETC 218, 1219-1227.	Qq1 1 0.7 1.9	84314 rgBT 9
68	Prevalence and incidence of anal human papillomavirus infection in Mexican men: Need for universal prevention policies. Salud Publica De Mexico, 2018, 60, 645.	0.1	4
69	Incidence of external genital lesions related to human papillomavirus among Mexican men. A cohort study. Salud Publica De Mexico, 2018, 60, 633.	0.1	6
70	HPV-6 molecular variants association with the development of genital warts in men: The HIM Study. Journal of Infectious Diseases, 2017, 215, jiw600.	1.9	11
71	Dietary intake of selected nutrients and persistence of HPV infection in men. International Journal of Cancer, 2017, 141, 757-765.	2.3	15
72	Comparison of the Natural History of Genital HPV Infection among Men by Country: Brazil, Mexico, and the United States. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1043-1052.	1.1	18

#	Article	IF	Citations
73	Prevalence and Concordance of Cutaneous Beta Human Papillomavirus Infection at Mucosal and Cutaneous Sites. Journal of Infectious Diseases, 2017, 216, 92-96.	1.9	47
74	HPV serostatus pre- and post-vaccination in a randomized phase II preparedness trial among young Western Cape, South African women: The evri trial. Papillomavirus Research (Amsterdam,) Tj ETQq0 0 0 rgBT /O	verko <b>s</b> k 10	) Tf <b>5</b> 0 697 Td
75	Isolation and characterization of a novel putative human polyomavirus. Virology, 2017, 506, 45-54.	1.1	77
76	Comparison of anal HPV natural history among men by country of residence: Brazil, Mexico, and the United States. Journal of Infection, 2017, 75, 35-47.	1.7	22
77	Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials. Papillomavirus Research (Amsterdam, Netherlands), 2017, 3, 105-115.	4.5	22
78	Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet, The, 2017, 390, 2143-2159.	6.3	314
79	Concordance of Beta-papillomavirus across anogenital and oral anatomic sites of men: The HIM Study. Virology, 2017, 510, 55-59.	1.1	14
80	Cutaneous HPV and alpha-mucosal 9-valent HPV sero-status associations. Papillomavirus Research (Amsterdam, Netherlands), 2017, 4, 54-57.	4.5	2
81	Human Immunodeficiency Virus Status Differentially Associated With Genital and Anal Human Papillomavirus Infection Among Chinese Men Who Have Sex With Men: A Cross-Sectional Survey. Sexually Transmitted Diseases, 2017, 44, 656-662.	0.8	10
82	Countryâ€specific HPVâ€related genital disease among men residing in Brazil, Mexico and The United States: The HIM study. International Journal of Cancer, 2017, 140, 337-345.	2.3	8
83	Human Papillomavirus Vaccination Rates in Young Cancer Survivors. Journal of Clinical Oncology, 2017, 35, 3582-3590.	0.8	44
84	Relationship between human papillomavirus and penile cancerâ€"implications for prevention and treatment. Translational Andrology and Urology, 2017, 6, 791-802.	0.6	68
85	Recurring infection with ecologically distinct HPV types can explain high prevalence and diversity. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13573-13578.	3.3	59
86	HPV-11 variability, persistence and progression to genital warts in men: the HIM study. Journal of General Virology, 2017, 98, 2339-2342.	1.3	10
87	HPV Population Profiling in Healthy Men by Next-Generation Deep Sequencing Coupled with HPV-QUEST. Viruses, 2016, 8, 28.	1.5	7
88	Diversity of beta-papillomavirus at anogenital and oral anatomic sites of men: The HIM Study. Virology, 2016, 495, 33-41.	1.1	39
89	Incidence, Duration, Persistence, and Factors Associated With High-risk Anal Human Papillomavirus Persistence Among HIV-negative Men Who Have Sex With Men: A Multinational Study. Clinical Infectious Diseases, 2016, 62, 1367-1374.	2.9	44
90	Missing the Target for Routine Human Papillomavirus Vaccination: Consistent and Strong Physician Recommendations Are Lacking for 11- to 12-Year-Old Males. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1435-1446.	1.1	42

#	Article	IF	CITATIONS
91	HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 141-144.	4.5	9
92	The Role of Human Papilloma Virus in Penile Carcinogenesis and Preneoplastic Lesions. Urologic Clinics of North America, 2016, 43, 419-425.	0.8	43
93	Sequential Acquisition of Anal Human Papillomavirus (HPV) Infection Following Genital Infection Among Men Who Have Sex With Women: The HPV Infection in Men (HIM) Study. Journal of Infectious Diseases, 2016, 214, 1180-1187.	1.9	26
94	Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies. Ca-A Cancer Journal for Clinicians, 2016, 66, 481-495.	157.7	55
95	Human Papillomavirus Prevalence Among 88 Male Virgins Residing in Brazil, Mexico, and the United States. Journal of Infectious Diseases, 2016, 214, 1188-1191.	1.9	7
96	Cutaneous beta human papillomaviruses and the development of male external genital lesions: A case-control study nested within the HIM Study. Virology, 2016, 497, 314-322.	1.1	8
97	Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study. Cancer Research, 2016, 76, 6066-6075.	0.4	12
98	Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. Journal of Infectious Diseases, 2016, 214, 1276-1283.	1.9	65
99	Monitoring the impact of HPV vaccine in malesâ€"Considerations and challenges. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 106-111.	4.5	20
100	The content and context of physicians' communication with males about human papillomavirus vaccination. Human Vaccines and Immunotherapeutics, 2016, 12, 1511-1518.	1.4	19
101	Cervical HPV natural history among young Western Cape, South African women: The randomized control EVRI Trial. Journal of Infection, 2016, 72, 60-69.	1.7	6
102	Human Papillomavirus (HPV) L1 Serum Antibodies and the Risk of Subsequent Oral HPV Acquisition in Men: The HIM Study. Journal of Infectious Diseases, 2016, 214, 45-48.	1.9	21
103	Salivary secretory leukocyte protease inhibitor (SLPI) and head and neck cancer: The Cancer Prevention Study II Nutrition Cohort. Oral Oncology, 2016, 55, 1-5.	0.8	12
104	Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study. European Urology, 2016, 69, 166-173.	0.9	59
105	Seroprevalence of cutaneous human papillomaviruses (HPVs) among men in the multinational HPV Infection in Men study. Journal of General Virology, 2016, 97, 3291-3301.	1.3	13
106	Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study. PLoS ONE, 2016, 11, e0167173.	1.1	15
107	Seroprevalence of Cutaneous Human Papillomaviruses and the Risk of External Genital Lesions in Men: A Nested Case-Control Study. PLoS ONE, 2016, 11, e0167174.	1.1	3
108	Impact of Global HPV Vaccination for Male Genital Disease., 2016,, 31-36.		0

#	Article	IF	Citations
109	Role of histological findings and pathologic diagnosis for detection of human papillomavirus infection in men. Journal of Medical Virology, 2015, 87, 1777-1787.	2.5	9
110	Seroconversion following anal and genital HPV infection in men: The HIM study. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 109-115.	4.5	47
111	Human Papillomavirus Virus (HPV) Genotype- and Age-Specific Analyses of External Genital Lesions Among Men in the HPV Infection in Men (HIM) Study. Journal of Infectious Diseases, 2015, 211, 1060-1067.	1.9	59
112	A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. New England Journal of Medicine, 2015, 372, 711-723.	13.9	1,090
113	Long-term Persistence of Oral Human Papillomavirus Type 16: The HPV Infection in Men (HIM) Study. Cancer Prevention Research, 2015, 8, 190-196.	0.7	55
114	Human papillomavirus vaccine intentions among males: A test of the Parallel Processing Model. Journal of Health Psychology, 2015, 20, 427-437.	1.3	6
115	High HIV, HPV, and STI Prevalence Among Young Western Cape, South African Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 227-235.	0.9	29
116	The Natural History of Genital Human Papillomavirus Among HIV-Negative Men Having Sex With Men and Men Having Sex With Women. Journal of Infectious Diseases, 2015, 212, 202-212.	1.9	19
117	Immunogenicity and safety of Gardasil among mid-adult aged men (27–45 years)—The MAM Study. Vaccine, 2015, 33, 5640-5646.	1.7	51
118	An analysis of HPV infection incidence and clearance by genotype and age in men: The HPV Infection in Men (HIM) Study. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 126-135.	4.5	23
119	The Beginning of the End: Vaccine Prevention of HPV-Driven Cancers. Journal of the National Cancer Institute, 2015, 107, djv128-djv128.	3.0	7
120	Alcohol consumption and prevalence of human papillomavirus (HPV) infection among US men in the HPV in Men (HIM) study. Sexually Transmitted Infections, 2015, 91, 61-67.	0.8	27
121	Recurrent <i>BRCA1</i> and <i>BRCA2</i> Mutations in Mexican Women with Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 498-505.	1.1	29
122	<scp>E</scp> UROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirusâ€related cancer incidence by gender and anatomic site of infection. International Journal of Cancer, 2015, 136, 2752-2760.	2.3	243
123	Alternative dosage schedules with HPV virus-like particle vaccines. Expert Review of Vaccines, 2014, 13, 1027-1038.	2.0	41
124	Age-related variation in sexual behaviours among heterosexual men residing in Brazil, Mexico and the USA. Journal of Family Planning and Reproductive Health Care, 2014, 40, 261-269.	0.9	3
125	Adolescent sexual activity and cancer risk: physicians' duty to inform?. Current Medical Research and Opinion, 2014, 30, 1827-1831.	0.9	8
126	Prospective Study of Seroreactivity to JC Virus T-Antigen and Risk of Colorectal Cancers and Adenomas. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2591-2596.	1.1	10

#	Article	IF	Citations
127	Case–control study of genusâ€beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma. International Journal of Cancer, 2014, 134, 2231-2244.	2.3	56
128	A prospective analysis of smoking and human papillomavirus infection among men in the HPV in Men Study. International Journal of Cancer, 2014, 134, 2448-2457.	2.3	26
129	The Role of Monogamy and Duration of Heterosexual Relationships in Human Papillomavirus Transmission. Journal of Infectious Diseases, 2014, 209, 1007-1015.	1.9	31
130	High genital prevalence of cutaneous human papillomavirus DNA on male genital skin: the HPV Infection in Men Study. BMC Infectious Diseases, 2014, 14, 677.	1.3	24
131	Sexual Behaviors and Other Risk Factors for Oral Human Papillomavirus Infections in Young Women. Sexually Transmitted Diseases, 2014, 41, 486-492.	0.8	38
132	Physicians' Human Papillomavirus Vaccine Recommendations in the Context of Permissive Guidelines for Male Patients: A National Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2126-2135.	1.1	30
133	Human Papillomavirus Vaccine Administration Among Medicaid Providers Who Consistently Recommended Vaccination. Sexually Transmitted Diseases, 2014, 41, 24-28.	0.8	5
134	Physicians' Human Papillomavirus Vaccine Recommendations, 2009 and 2011. American Journal of Preventive Medicine, 2014, 46, 80-84.	1.6	91
135	Male circumcision and the incidence and clearance of genital human papillomavirus (HPV) infection in men: the HPV Infection in men (HIM) cohort study. BMC Infectious Diseases, 2014, 14, 75.	1.3	42
136	Incidence, Clearance, and Disease Progression of Genital Human Papillomavirus Infection in Heterosexual Men. Journal of Infectious Diseases, 2014, 210, 192-199.	1.9	42
137	Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1997-2008.	1.1	137
138	Factors Associated With Medicaid Providers' Recommendation of the HPV Vaccine to Low-Income Adolescent Girls. Journal of Adolescent Health, 2014, 54, 190-196.	1.2	48
139	Natural History of Cutaneous Human Papillomavirus (HPV) Infection in Men: The HIM Study. PLoS ONE, 2014, 9, e104843.	1.1	54
140	Provider factors associated with disparities in human papillomavirus vaccination among lowâ€income 9― to 17â€yearâ€old girls. Cancer, 2013, 119, 621-628.	2.0	30
141	Broad HPV distribution in the genital region of men from the HPV infection in men (HIM) study. Virology, 2013, 443, 214-217.	1.1	35
142	Do Florida Medicaid Providers' Barriers to HPV Vaccination Vary Based on VFC Program Participation?. Maternal and Child Health Journal, 2013, 17, 609-615.	0.7	21
143	Men Who Purchase Sex, Who Are They? An Interurban Comparison. Journal of Urban Health, 2013, 90, 1166-1180.	1.8	12
144	Quantification of secretory leukocyte protease inhibitor (SLPI) in oral gargle specimens collected using mouthwash. Journal of Immunological Methods, 2013, 400-401, 117-121.	0.6	11

#	Article	IF	Citations
145	Cutaneous human papillomavirus types detected on the surface of male external genital lesions: A case series within the HPV Infection in Men Study. Journal of Clinical Virology, 2013, 58, 652-659.	1.6	37
146	Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine, 2013, 31, 3849-3855.	1.7	42
147	Male circumcision and prevalence of genital human papillomavirus infection in men: a multinational study. BMC Infectious Diseases, 2013, 13, 18.	1.3	19
148	The Epidemiology and Control of Human Papillomavirus Infection and Clinical Disease., 2013, , 315-352.		1
149	Case–Control Study of Cutaneous Human Papillomavirus Infection in Basal Cell Carcinoma of the Skin. Journal of Investigative Dermatology, 2013, 133, 1512-1520.	0.3	48
150	Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet, The, 2013, 382, 877-887.	6.3	239
151	Association of Chlamydia trachomatis Infection and Herpes Simplex Virus Type 2 Serostatus With Genital Human Papillomavirus Infection in Men. Sexually Transmitted Diseases, 2013, 40, 508-515.	0.8	28
152	Consistent Condom Use Reduces the Genital Human Papillomavirus Burden Among High-Risk Men: The HPV Infection in Men Study. Journal of Infectious Diseases, 2013, 208, 373-384.	1.9	55
153	Racial Differences in the Incidence and Clearance of Human Papilloma Virus (HPV): The HPV in Men (HIM) Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1762-1770.	1.1	14
154	Concordance of human papillomavirus types detected on the surface and in the tissue of genital lesions in men. Journal of Medical Virology, 2013, 85, 1561-1566.	2.5	18
155	Human papillomavirus infection in head and neck cancer: The role of the secretory leukocyte protease inhibitor. Oncology Reports, 2013, 29, 1962-1968.	1.2	42
156	Male Human Papillomavirus Prevalence and Association With Condom Use in Brazil, Mexico, and the United States. Journal of Infectious Diseases, 2012, 205, 1287-1293.	1.9	30
157	Evolutionary Ecology of Human Papillomavirus: Trade-offs, Coexistence, and Origins of High-Risk and Low-Risk Types. Journal of Infectious Diseases, 2012, 205, 272-279.	1.9	41
158	HPV-related information sharing and factors associated with US men's disclosure of an HPV test result to their female sexual partners. Sexually Transmitted Infections, 2012, 88, 171-176.	0.8	3
159	Seroprevalence of Human Papillomavirus (HPV) Type 6 and 16 Vary by Anatomic Site of HPV Infection in Men. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1542-1546.	1.1	45
160	Risk Factors for Incident Condyloma in a Multinational Cohort of Men: The HIM Study. Journal of Infectious Diseases, 2012, 205, 789-793.	1.9	29
161	Genital Human Papillomavirus (HPV) Concordance in Heterosexual Couples. Journal of Infectious Diseases, 2012, 206, 202-211.	1.9	37
162	Cognitive and Emotional Responses to Human Papillomavirus Test Results in Men. American Journal of Health Behavior, 2012, 36, 770-785.	0.6	7

#	Article	IF	CITATIONS
163	Sunlight Exposure and Cutaneous Human Papillomavirus Seroreactivity in Basal Cell and Squamous Cell Carcinomas of the Skin. Journal of Infectious Diseases, 2012, 206, 399-406.	1.9	23
164	Human Papillomavirus Type Distribution Among Heterosexual Couples. Journal of Lower Genital Tract Disease, 2012, 16, 10-15.	0.9	8
165	Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old. Vaccine Journal, 2012, 19, 261-267.	3.2	90
166	Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men. Cancer Research, 2012, 72, 676-685.	0.4	57
167	HPV in Female Partners Increases Risk of Incident HPV Infection Acquisition in Heterosexual Men in Rural Central Mexico. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1956-1965.	1.1	13
168	Prevention of Invasive Cervical Cancer in the United States: Past, Present, and Future. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1402-1408.	1,1	81
169	Case–Control Study of Cutaneous Human Papillomaviruses in Squamous Cell Carcinoma of the Skin. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1303-1313.	1.1	64
170	Male Circumcision and Genital Human Papillomavirus. Sexually Transmitted Diseases, 2012, 39, 104-113.	0.8	102
171	Human papillomavirus vaccination. Aids, 2012, 26, 2251-2252.	1.0	6
172	Smoking and Human Papillomavirus (HPV) Infection in the HPV in Men (HIM) Study. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 102-110.	1.1	50
173	HPV—Beyond Cervical Cancer (Online Resource Center). American Journal of Medicine, 2012, 125, S1.	0.6	9
174	Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin $\hat{a}\in$ " a case $\hat{a}\in$ "control study. BMC Cancer, 2012, 12, 417.	1.1	53
175	Behavioral and sociodemographic risk factors for serological and DNA evidence of HPV6, 11, 16, 18 infections. Cancer Epidemiology, 2012, 36, e183-e189.	0.8	7
176	Updating the Natural History of Human Papillomavirus and Anogenital Cancers. Vaccine, 2012, 30, F24-F33.	1.7	303
177	Quadrivalent Human Papillomavirus (HPV) Types 6, $11$ , $16$ , $18$ Vaccine for the Prevention of Genital Warts in Males. Drugs in R and D, 2012, $12$ , $235$ - $238$ .	1.1	2
178	Race and prevalence of human papillomavirus infection among men residing in Brazil, Mexico and the United States. International Journal of Cancer, 2012, 131, E282-91.	2.3	29
179	Case–control study of smoking and non-melanoma skin cancer. Cancer Causes and Control, 2012, 23, 245-254.	0.8	28
180	Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine. Drugs, 2011, 71, 591-602.	4.9	23

#	Article	IF	CITATIONS
181	Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. New England Journal of Medicine, 2011, 364, 401-411.	13.9	955
182	Ethnic and racial differences in HPV knowledge and vaccine intentions among men receiving HPV test results. Vaccine, 2011, 29, 4013-4018.	1.7	36
183	Health beliefs and attitudes associated with HPV vaccine intention among young gay and bisexual men in the southeastern United States. Vaccine, 2011, 29, 8060-8065.	1.7	82
184	Missed clinical opportunities: Provider recommendations for HPV vaccination for 11–12 year old girls are limited. Vaccine, 2011, 29, 8634-8641.	1.7	174
185	Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet, The, 2011, 377, 932-940.	6.3	399
186	Genital HPV infection and related lesions in men. Preventive Medicine, 2011, 53, S36-S41.	1.6	90
187	Performance of the Quantitative Food Frequency Questionnaire Used in the Brazilian Center of the Prospective Study Natural History of Human Papillomavirus Infection in Men: The HIM Study. Journal of the American Dietetic Association, 2011, 111, 1045-1051.	1.3	12
188	Incidence and Human Papillomavirus (HPV) Type Distribution of Genital Warts in a Multinational Cohort of Men: The HPV in Men Study. Journal of Infectious Diseases, 2011, 204, 1886-1892.	1.9	66
189	HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia. New England Journal of Medicine, 2011, 365, 1576-1585.	13.9	810
190	Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum Vaccin, 2011, 7, 768-775.	2.4	31
191	The Epidemiology of Oral HPV Infection among a Multinational Sample of Healthy Men. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 172-182.	1.1	169
192	External Genital Human Papillomavirus Prevalence and Associated Factors Among Heterosexual Men on 5 Continents. Journal of Infectious Diseases, 2011, 203, 58-65.	1.9	89
193	Age-Specific Prevalence of and Risk Factors for Anal Human Papillomavirus (HPV) among Men Who Have Sex with Women and Men Who Have Sex with Men: The HPV in Men (HIM) Study. Journal of Infectious Diseases, 2011, 203, 49-57.	1.9	191
194	Human Papillomavirus (HPV) 6, 11, 16, and 18 Seroprevalence Is Associated with Sexual Practice and Age: Results from the Multinational HPV Infection in Men Study ( <i>HIM</i> Study). Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 990-1002.	1.1	65
195	The Prevalence of Genital HPV and Factors Associated With Oncogenic HPV Among Men Having Sex With Men and Men Having Sex With Women and Men: The HIM Study. Sexually Transmitted Diseases, 2011, 38, 932-940.	0.8	56
196	HPV Vaccination to Prevent HIV Infection: Time for Randomized Controlled Trials. Sexually Transmitted Diseases, 2011, 38, 640-643.	0.8	21
197	Six-Month Incidence, Persistence, and Factors Associated With Persistence of Anal Human Papillomavirus in Men: The HPV in Men Study. Journal of Infectious Diseases, 2011, 204, 1711-1722.	1.9	108
198	Clustering of Human Papillomavirus (HPV) Types in the Male Genital Tract: The HPV in Men (HIM) Study. Journal of Infectious Diseases, 2011, 204, 1500-1504.	1.9	22

#	Article	IF	CITATIONS
199	Oral Human Papillomavirus in Healthy Individuals: A Systematic Review of the Literature. Sexually Transmitted Diseases, 2010, 37, 386-391.	0.8	249
200	Testâ€"Retest Reliability and Predictors of Unreliable Reporting for a Sexual Behavior Questionnaire for U.S. Men. Archives of Sexual Behavior, 2010, 39, 1343-1352.	1.2	7
201	Epidemiology and pathology of HPV disease in males. Gynecologic Oncology, 2010, 117, S15-S19.	0.6	97
202	Epidemiologic Factors Associated with Seropositivity to Human Papillomavirus Type 16 and 18 Virus–Like Particles and Risk of Subsequent Infection in Men. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 511-516.	1.1	33
203	Risk Factors for Cutaneous Human Papillomavirus Seroreactivity among Patients Undergoing Skin Cancer Screening in Florida. Journal of Infectious Diseases, 2010, 201, 760-769.	1.9	26
204	Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in Men Who Have Sex with Women: A Crossâ€National Study. Journal of Infectious Diseases, 2010, 201, 1498-1508.	1.9	80
205	Human Papillomavirus Vaccine Intentions Among Men Participating in a Human Papillomavirus Natural History Study Versus a Comparison Sample. Sexually Transmitted Diseases, 2010, 37, 644-652.	0.8	24
206	Human papillomavirus vaccine intentions among men participating in a human papillomavirus natural history study versus a comparison sample. Sexually Transmitted Diseases, 2010, 37, 644-52.	0.8	18
207	Test-Retest Reliability of a Sexual Behavior Interview for Men Residing in Brazil, Mexico, and the United States: The HPV in Men (HIM) Study. American Journal of Epidemiology, 2009, 170, 965-974.	1.6	33
208	Associations between Male Anogenital Human Papillomavirus Infection and Circumcision by Anatomic Site Sampled and Lifetime Number of Female Sex Partners. Journal of Infectious Diseases, 2009, 199, 7-13.	1.9	82
209	Multiple-Type Human Papillomavirus Infection in Male Anogenital Sites: Prevalence and Associated Factors. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1077-1083.	1.1	74
210	Factors Associated with Acquisition and Clearance of Human Papillomavirus Infection in a Cohort of US Men: A Prospective Study. Journal of Infectious Diseases, 2009, 199, 362-371.	1.9	115
211	Circumcision and sexual behavior: Factors independently associated with human papillomavirus detection among men in the HIM study. International Journal of Cancer, 2009, 124, 1251-1257.	2.3	111
212	Racial and ethnic disparities in the incidence of invasive cervical cancer in Florida. Cancer, 2009, 115, 3991-4000.	2.0	20
213	Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. International Journal of Cancer, 2008, 123, 2337-2342.	2.3	31
214	Reliability of sample collection and laboratory testing for HPV Detection in Men. Journal of Virological Methods, 2008, 149, 136-143.	1.0	39
215	Epidemiology of Human Papillomavirus Infection in Men, Cancers other than Cervical and Benign Conditions. Vaccine, 2008, 26, K17-K28.	1.7	297
216	The Case for a Gender-Neutral (Universal) Human Papillomavirus Vaccination Policy in the United States: Point. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 805-808.	1.1	40

#	Article	IF	Citations
217	The Human Papillomavirus Infection in Men Study: Human Papillomavirus Prevalence and Type Distribution among Men Residing in Brazil, Mexico, and the United States. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2036-2043.	1.1	294
218	Prevalence of and Risk Factors for Anal Human Papillomavirus Infection in Heterosexual Men. Journal of Infectious Diseases, 2008, 197, 1676-1684.	1.9	93
219	Ageâ€Specific Prevalence, Incidence, and Duration of Human Papillomavirus Infections in a Cohort of 290 US Men. Journal of Infectious Diseases, 2008, 198, 827-835.	1.9	167
220	Correlates of Human Papillomavirus Viral Load with Infection Site in Asymptomatic Men. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3573-3576.	1.1	32
221	Risk Factors for Anogenital Human Papillomavirus Infection in Men. Journal of Infectious Diseases, 2007, 196, 1137-1145.	1.9	106
222	Impact of Baseline Covariates on the Immunogenicity of a Quadrivalent (Types 6, 11, 16, and 18) Human Papillomavirus Virusâ€Likeâ€Particle Vaccine. Journal of Infectious Diseases, 2007, 196, 1153-1162.	1.9	113
223	The Optimal Anatomic Sites for Sampling Heterosexual Men for Human Papillomavirus (HPV) Detection: The HPV Detection in Men Study. Journal of Infectious Diseases, 2007, 196, 1146-1152.	1.9	176
224	Human Papillomavirus Prevalence and Type Distribution in Male Anogenital Sites and Semen. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1107-1114.	1.1	146
225	Human papillomavirus vaccination in males. Gynecologic Oncology, 2007, 107, S24-S26.	0.6	69
226	Prevalence of HPV Infection among Men: A Systematic Review of the Literature. Journal of Infectious Diseases, 2006, 194, 1044-1057.	1.9	503
227	Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 2006, 24, 5571-5583.	1.7	380
228	Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology, The, 2005, 6, 271-278.	5.1	1,400
229	Condom Use and Other Factors Affecting Penile Human Papillomavirus Detection in Men Attending a Sexually Transmitted Disease Clinic. Sexually Transmitted Diseases, 2004, 31, 601-607.	0.8	111
230	Human Papillomavirus Infection in Men Attending a Sexually Transmitted Disease Clinic. Journal of Infectious Diseases, 2003, 187, 1064-1070.	1.9	117
231	Incidence, Prevalence, and Clearance of Typeâ€Specific Human Papillomavirus Infections: The Young Women's Health Study. Journal of Infectious Diseases, 2002, 186, 462-469.	1.9	247
232	Clearance of oncogenic human papillomavirus (HPV) infection: effect of smoking (United States). Cancer Causes and Control, 2002, 13, 839-846.	0.8	137
233	Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults. International Journal of Cancer, 2001, 95, 7-11.	2.3	79
234	Improvement in dietary intake estimates through the combined use of different approaches. Revista De Nutricao, 0, 32, .	0.4	0